Optimizing Sustainability in Pharmaceutical Companies with AHP: A Framework for Reducing Carbon Footprints
AHPによる製薬企業の持続可能性最適化：カーボンフットプリント削減のためのフレームワーク (AI 翻訳)
Sachin Sudhakar Birari, Dr. Nilesh R. Berad
🤖 gxceed AI 要約
日本語
この研究は、ファジィAHPを用いて製薬企業の持続可能性最適化の主要因子を分析した。規制遵守と報告の透明性、持続可能な臨床試験が最も重要と判明。廃棄物削減やグリーン包装なども中程度の寄与。経営者はコンプライアンス強化と透明性向上に注力すべき。
English
This study uses Fuzzy AHP to analyze key factors for optimizing sustainability in pharmaceutical companies, with regulatory compliance, transparency, and sustainable clinical trials identified as most critical. Mid-level factors include waste minimization and green packaging. Managers should focus on compliance and transparent reporting.
Unofficial AI-generated summary based on the public title and abstract. Not an official translation.
📝 gxceed 編集解説 — Why this matters
日本のGX文脈において
日本の製薬企業はSSBJやTCFDに基づく開示要請に直面しており、本フレームワークは持続可能性活動の優先順位付けに有用である。
In the global GX context
For global pharma, regulatory compliance and transparent reporting are top priorities under ISSB and CSRD frameworks. This AHP-based ranking helps companies allocate resources effectively.
👥 読者別の含意
🔬研究者:Provides a structured prioritization of sustainability factors using MCDM, filling a gap in empirical ranking for pharma.
🏢実務担当者:Lists actionable priorities (compliance, transparency, sustainable clinical trials) for carbon footprint reduction and ESG disclosure.
🏛政策担当者:Highlights regulatory compliance and transparency as key levers; could inform standards and reporting requirements.
📄 Abstract（原文）
Purpose: The aim of the study is to analyse the key factors that optimize sustainability in pharmaceutical companies. The study seeks to develop a systematic framework that enhances environmental, social, and economic performance within the pharmaceutical sector. Design/Methodology/Approach: The technique used in this study is a Multi-Criteria Decision-Making method (Fuzzy Analytic Hierarchy Process) to evaluate and prioritize sustainability practices adopted by pharmaceutical companies. Findings: The study identified Regulatory Compliance and Standards, Transparency and Reporting, and Sustainable Clinical Trials as the most critical factors for optimizing sustainability in pharmaceutical companies. Mid-level contributors included waste minimization, sustainable packaging, and green building practices, while supply chain optimization and product lifecycle management were ranked lower in importance. Implications: The results suggest that managers should focus on strengthening compliance, transparent reporting, and clinical trial sustainability to achieve meaningful progress. Policymakers may consider reinforcing regulatory frameworks, while socially, greater emphasis on eco-friendly practices and accountability can foster public trust and support long-term sustainability goals. Originality: This study is novel as it applies a structured decision-making framework (Fuzzy Analytic Hierarchy Process) to systematically rank and evaluate sustainability factors in the pharmaceutical industry, an area where empirical prioritization has been limited.
🔗 Provenance — このレコードを発見したソース
- openalex https://doi.org/10.66635/na230f09first seen 2026-06-23 05:35:35
🔔 こうした論文の新着を逃したくない方は キーワードアラート に登録（無料・3キーワードまで）。
gxceed は公開メタデータに基づく研究支援データセットです。要約・翻訳・解説は AI 支援で生成されています。 最終的な解釈・検証は利用者が原典資料に基づいて行うことを前提とします。